From panels to exomes, or whole genomes, for sequencing hematological malignancies?

From panels to exomes, or whole genomes, for sequencing hematological malignancies?

Prof. Torsten Haferlach CEO and Co-founder, MLL Munich Leukemia Laboratory
Topic: Cancer Research

Professor Torsten Haferlach, Head of Munich Leukemia Laboratory (MLL), will present their experience with large-scale sequencing including the use of artificial intelligence strategies to perform whole genome sequencing (WGS) and RNA sequencing on 5000 samples.



American Society of Clinical Oncology (ASCO) Annual Meeting 2019
Chicago, IL | North America
Topic: Cancer Genomics
Cancer Genomics Consortium (CGC) Annual Meeting 2019
Nashville, TN | North America
Topic: Cancer Genomics
CHI Next Generation Dx Summit 2019
Washington, DC | North America
Topic: Cancer Genomics